Brief: Cumberland Pharmaceuticals Says U.S. FDA Accepted NDA For Methotrexate Product Line

Cumberland Pharmaceuticals

14/01/2019 11:41

Jan 14 (Reuters) - Cumberland Pharmaceuticals Inc  CPIX.O :
    * CUMBERLAND PHARMACEUTICALS - ON JAN 4, U.S. FDA ACCEPTED
FOR
REVIEW NDA FOR APPROVAL OF METHOTREXATE PRODUCT LINE
    * CUMBERLAND PHARMACEUTICALS - NDA ACCEPTED FOR FILING WITH
PDUFA
ACTION DATE PROJECTED FOR NOV 2019
    * CUMBERLAND SAYS REMITTED PAYMENT OF $1.3 MILLION TO FDA
FOR
PDUFA APPLICATION FEE ASSOCIATED WITH METHOTREXATE PRODUCT LINE
APPLICATION - SEC FILING

Source text: (https://bit.ly/2AJHvsS)
Further company coverage:  CPIX.O 

 ((Reuters.Briefs@thomsonreuters.com;))